<<  October 2019  >>
 Mo  Tu  We  Th  Fr  Sa  Su 
   1  2  3  4  5  6
  7  8  910111213
14151617181920
21222324252627
28293031   

Contact details

Georgios A. Spyroulias, PhD.
Department of Pharmacy
University of Patras
Panepistimioupoli-Rion,
GR-26504 Patras, GREECE
Tel:    +30.2610.969950 (office)
+30.2610.969951 (terra silico)
+30.2610.969952 (terra vitro)
Fax:    +30.2610.969950
Email:  G.A.Spyroulias@upatras.gr

Site Statistics

mod_vvisit_countermod_vvisit_countermod_vvisit_countermod_vvisit_countermod_vvisit_countermod_vvisit_countermod_vvisit_countermod_vvisit_counter
mod_vvisit_counterToday283
mod_vvisit_counterYesterday2345
mod_vvisit_counterThis week17274
mod_vvisit_counterLast week15893
mod_vvisit_counterThis month44299
mod_vvisit_counterLast month65159
mod_vvisit_counterAll1867503

Online (20 minutes ago): 31
Your IP: 18.207.134.98
,
Now is: 2019-10-20 03:05
Somatostatin analogues (Octreotate
Somatostatin analogues (Octreotate). Somatostatin, a cyclic tetradecapeptide also known as somatotropin release inhibit factor (SRIF), plays a prominent role in the regulation of various biological functions such as the control of growth hormone, glucagon or insulin release from its target cells, acting among others as a neuromodulator and neurotransmitter in the central nervous system. Somatostatins exert their actions after binding to high affinity G protein-coupled receptors including five subtypes. These receptors are expressed in a large variety of human tissues and are noticeably up-regulated in certain types of tumors, especially the sst2. Additionally, synthetic somatostatin analogues radiolabeled with a variety of metallic radionuclides have been used as alternative new routes to diagnosis and therapy of sst-expressing tumors. These derivatives are usually preserving the somatostatin pharmacophore core comprised by Phe-DTrp-Lys-Thr residues while carrying a suitable chelator at the N-terminus which serves as the metal binding site, such as the cyclic octapeptide octreotide (or Sandostatin). The NMR conformational properties of [Tyr3]octreotate (DPhe-Cys-Tyr-DTrp-Lys-Thr-Cys-Thr-COOH; Cys2-Cys7 disulfide bridged) and analogues (Demotate 1), have been determined (PDB: 1YL8 & 1YL9).